Interventional - Procedure
The objective of the LAAOS III study is to determine if removing the left atrial appendage can reduce stroke and other complications on top of usual therapy.
The first occurrence of ischemic stroke* or transient ischemic attack with positive neuroimaging or systemic arterial embolism over the duration of follow-up.
Secondary outcomes over the duration of follow-up (unless otherwise specified) are:
1) All cause stroke or transient ischemic attack with positive neuroimaging or systemic arterial embolism.
2) Composite of ischemic stroke* or transient ischemic attack with positive neuroimaging or systemic arterial embolism or death.
3) Ischemic stroke *or transient ischemic attack with positive neuroimaging or systemic arterial embolism occurring more than 30 days after surgery.
4) All cause death.
1) Hospitalization for heart failure.
2) Operative safety outcomes.
a. Chest tube output in the first post-operative 24 hours.
b. Re-operation for bleeding within the first 48 hours post-surgery.
c. 30-day mortality
3) Major bleed.
4) Myocardial infarction
* Ischemic stroke is defined as any stroke that is not documented as primary hemorrhagic.
All components of composite outcomes will also be reported individually.LAAOS III Slides - Download PDF
Interventional - Procedure
Randomized, blinded, multicenter
2012 - 2021
Richard Whitlock is Associate Professor, Department of Surgery, McMaster University, Scientist in the Perioperative and Surgery program at PHRI, and a cardiac surgeon and intensive care physician at Hamilton Health Sciences. His clinical focus is on aortic valve intervention and aortic surgery. He is a lead investigator for the CIHR funded studies SIRS, LAAOS III, and TRICS III, which have established a network of more than 120 centres to address important questions in his field.
He has published more than 90 articles in referred journals. Medically qualified at the University of Toronto, Richard received his specialist training in cardiac surgery and critical care medicine at McMaster University. In 2012, he received his PhD in clinical epidemiology.
Stuart Connolly is a Professor of Medicine at McMaster University and a cardiac electrophysiologist at Hamilton Health Sciences. He became a faculty member at McMaster University in 1983 and was awarded a full professorship in 1994. He was also appointed as the inaugural holder of the Salim Yusuf Chair in Cardiology at McMaster University.
He has published more than 270 scientific articles in the field, and is currently a member of the editorial boards for a number of prominent cardiology journals, including Heart, the American Heart Journal and the Journal of Pacing and Electrophysiology. His main research interests are focused on the evaluation of treatments for heart rhythm disorders. His academic career has been largely devoted to the design and execution of controlled clinical trials in this area.
He holds a Masters degree from Fordham University, New York, and an MD from McGill University in Montreal. He received his specialist training in cardiology at the University of Toronto and at Stanford University.
Associate Program Manager
Jessica Vincent has more than 15 years’ experience in coordinating and managing large, international clinical trials. As Associate Program Manager, she oversees interventional trials, registries, and observational research studies in the areas of perioperative medicine, cardiac surgery, and digital health.
She holds an Honours Bachelor of Science Degree from Queens University, and a Master of Clinical Epidemiology Degree from the University of Newcastle.
Back To Top